Mary Caffrey

Levittown

Executive Editor at MJH Life Sciences

Jersey politics and sports. No work zone.

Featured in: Favicon

mjhlifesciences.com

linkedin.com Favicon

patch.com

newsbreak.com Favicon

ajmc.com

pharmacytimes.com Favicon

onclive.com Favicon

realclearpolicy.com Favicon

curetoday.com Favicon

managedhealthcareexecutive.com + 8 more

Articles

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

1 week ago | ajmc.com | Mary Caffrey

The last time The American Journal of Managed Care (AJMC) hosted a meeting in Princeton, New Jersey, was 2014, as millions of Americans were gaining health coverage under the Affordable Care Act—some for the first time in their lives.
Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

1 week ago | ajmc.com | Mary Caffrey

By this fall, the FDA may approve a subcutaneous (SC) injection of the world’s top-selling cancer drug, pembrolizumab (Keytruda; Merck), that can be delivered to patients in 5 minutes or less.
Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

1 week ago | ajmc.com | Mary Caffrey

Previously treated patients with diffuse large B-cell lymphoma (DLBCL) who received epcoritamab plus chemoimmunotherapy had an 87% overall response rate (ORR), and 65% were able to receive autologous stem cell transplant (ASCT), according to trial data presented last week at the 30th European Hematology Association (EHA) Congress, held in Milan, Italy.
Supreme Court to Rule Whether Pro-Life Pregancy Center Can Avoid Subpoena

1 week ago | ajmc.com | Mary Caffrey

New Jersey’s investigation into whether a faith-based pregnancy center misled the public into thinking it provided referrals for abortion will remain on hold, as the Supreme Court of the United States agreed today to hear the center’s challenge to state efforts to subpoena records. The justices will hear an appeal from First Choice Women’s Resource Centers, which seeks to block a 2023 subpoena from New Jersey Attorney General Matthew Platkin, a Democrat.
States Accept Increased Purdue Pharma Offer of $7.4B to Settle Opioid Suits

1 week ago | ajmc.com | Mary Caffrey

Fifty-five states and US territories have agreed to a $7.4 billion settlement from Purdue Pharma and its owners, the Sackler family, who seek to resolve claims involving the drugmaker’s pain medication OxyContin, which is blamed for the nation’s opioid addiction crisis. According to a statement from New York Attorney General Letitia James, whose office led the settlement talks, the new offer includes approximately $6.5 billion from the Sackler family and about $900 million from Purdue Pharma.
Disparities, Worsening Inequality of Growing RA Burden, Reveals AI-Driven Study

1 week ago | ajmc.com | Mary Caffrey |Hayden E. Klein

Since 1980, the global prevalence of rheumatoid arthritis (RA) has risen sharply, with incidence growing 13.2% over 3 decades from 1990 to 2021, according to a study published today in Annals of the Rheumatic Diseases.1 In addition, there are significant regional disparities and a shifting age profile.
Hope S. Rugo, MD, Discusses Retreatment for HER2+ Breast Cancer With Trastuzumab Deruxtecan After ILD

1 week ago | ajmc.com | Mary Caffrey

The antibody drug conjugate (ADC) trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo) has provided a new treatment option for thousands of patients with HER2+ breast cancer.1-3 Yet questions remain about the drug’s association with interstitial lung disease (ILD), which is seen in many cancers but can cause death in patients treated with this otherwise groundbreaking therapy.4 The consequences for patients with HER2+ breast cancer are such that guidelines call for stopping...
A Look at Those With Durable Responses to Epcoritamab in LBCL

2 weeks ago | ajmc.com | Mary Caffrey

Patients with large B-cell lymphoma (LBCL) who had complete responses (CR) after 2 years of treatment with subcutaneous epcoritamab (Epklinly, AbbVie/Genmab) were more likely to have lower tumor burden at baseline and had lower baseline ferritin levelsthan those who did not have a CR at 2 years, according to new look at data from the pivotal phase 2 EPCORE-NHL-1 trial.
Potential Impact of Loss of Coverage for Health Care Screenings: Constance Blunt, MD

2 weeks ago | ajmc.com | Pearl Steinzor |Mary Caffrey |Constance Blunt

Screening coverage is not just about medical tests, but about maintaining patient trust, reducing long-term health care costs, and ensuring accessible preventive care, says Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center. This transcript was lightly edited; captions were auto-generated. TranscriptIf insurance plans could eliminate free preventive screenings (employer or Medicaid), do you anticipate there would be fewer screenings? What kind of impact would this have?
Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

2 weeks ago | ajmc.com | Mary Caffrey

Patients with previously untreated high-tumor burden (HTB) follicular lymphoma (FL) showed promising results following treatment with a fixed-duration regimen of subcutaneous (SC) mosunetuzumab, according to data presented recently at the American Society of Clinical Oncology (ASCO) annual meeting.1 Interim results for patients in the phase 2 MorningSun trial (NCT05207670) follow those presented in late 2024 for a fixed-duration SC regimen in relapsed/refractory FL and in previously...